MaxCyte (MXCT) Financials

$2.82 +0.03 (+1.08%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$2.82 0.00 (-0.18%)

As of 05/2/2025 07:58 PM Eastern

Annual Income Statements for MaxCyte

This table shows MaxCyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-24	-38	-41
Consolidated Net Income / (Loss)	-24	-38	-41
Net Income / (Loss) Continuing Operations	-24	-38	-41
Total Pre-Tax Income	-24	-38	-41
Total Operating Income	-27	-48	-51
Total Gross Profit	39	37	32
Total Revenue	44	41	39
Operating Revenue	44	41	39
Total Cost of Revenue	5.10	4.74	7.10
Operating Cost of Revenue	5.10	4.74	7.10
Total Operating Expenses	67	85	83
Selling, General & Admin Expense	26	30	30
Marketing Expense	19	27	27
Research & Development Expense	20	24	22
Depreciation Expense	2.53	3.99	4.14
Total Other Income / (Expense), net	3.79	10	10
Interest & Investment Income	3.92	10	10
Income Tax Expense	0.00	0.00	0.00
Basic Earnings per Share	($0.23)	($0.37)	($0.39)
Weighted Average Basic Shares Outstanding	101.70M	103.27M	104.85M
Diluted Earnings per Share	($0.23)	($0.37)	($0.39)
Weighted Average Diluted Shares Outstanding	101.70M	103.27M	104.85M
Weighted Average Basic & Diluted Shares Outstanding	102.90M	104.13M	106.03M

This table shows MaxCyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-6.43	-4.81	-11	-11	-11	-5.28	-9.53	-9.38	-12	-11
Consolidated Net Income / (Loss)	-6.43	-4.81	-11	-11	-11	-5.28	-9.53	-9.38	-12	-11
Net Income / (Loss) Continuing Operations	-6.43	-4.81	-11	-11	-11	-5.28	-9.53	-9.38	-12	-11
Total Pre-Tax Income	-6.43	-4.81	-11	-11	-11	-5.28	-9.53	-9.38	-12	-11
Total Operating Income	-7.71	-6.75	-13	-13	-14	-8.10	-12	-12	-14	-13
Total Gross Profit	9.27	11	7.58	7.67	7.21	14	9.94	8.94	6.24	6.41
Total Revenue	11	12	8.58	9.04	8.00	16	11	10	8.16	8.69
Operating Revenue	11	12	8.58	9.04	8.00	16	11	10	8.16	8.69
Total Cost of Revenue	1.37	1.55	1.00	1.38	0.79	1.57	1.40	1.49	1.93	2.28
Operating Cost of Revenue	1.37	1.55	1.00	1.38	0.79	1.57	1.40	1.49	1.93	2.28
Total Operating Expenses	17	18	21	21	21	22	22	21	20	19
Selling, General & Admin Expense	6.44	5.65	7.50	7.66	6.82	8.09	7.10	7.64	7.75	7.21
Marketing Expense	4.51	5.38	6.30	6.44	7.05	7.20	7.37	6.62	6.21	6.47
Research & Development Expense	5.33	5.73	6.05	5.66	6.26	5.84	6.68	5.62	5.32	4.61
Depreciation Expense	0.71	0.87	0.91	0.98	1.03	1.06	1.07	1.03	1.02	1.02
Total Other Income / (Expense), net	1.28	1.94	2.30	2.56	2.70	2.82	2.75	2.59	2.50	2.30
Interest & Investment Income	1.39	1.95	2.30	2.56	2.70	2.82	2.75	2.59	2.50	2.30
Basic Earnings per Share	($0.06)	($0.05)	($0.11)	($0.10)	($0.11)	($0.05)	($0.09)	($0.09)	($0.11)	($0.10)
Weighted Average Basic Shares Outstanding	101.81M	101.70M	102.85M	103.06M	103.45M	103.27M	104.09M	104.64M	105.11M	104.85M
Weighted Average Diluted Shares Outstanding	101.81M	101.70M	103.05M	103.06M	103.45M	103.27M	104.54M	104.64M	105.11M	104.85M
Weighted Average Basic & Diluted Shares Outstanding	102.05M	102.90M	103.05M	103.50M	103.58M	104.13M	104.54M	105.09M	105.48M	106.03M

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-37	35	-19
Net Cash From Operating Activities	-15	-22	-28
Net Cash From Continuing Operating Activities	-15	-22	-28
Net Income / (Loss) Continuing Operations	-24	-38	-41
Consolidated Net Income / (Loss)	-24	-38	-41
Depreciation Expense	2.70	4.17	4.32
Amortization Expense	-2.67	-6.73	-5.77
Non-Cash Adjustments To Reconcile Net Income	11	17	16
Changes in Operating Assets and Liabilities, net	-2.07	1.91	-0.75
Net Cash From Investing Activities	-25	55	6.93
Net Cash From Continuing Investing Activities	-25	55	6.93
Purchase of Property, Plant & Equipment	-18	-3.70	-1.65
Purchase of Investments	-291	-255	-151
Sale of Property, Plant & Equipment	0.00	0.01	0.00
Sale and/or Maturity of Investments	285	314	159
Net Cash From Financing Activities	2.89	2.14	2.06
Net Cash From Continuing Financing Activities	2.89	2.14	2.06
Issuance of Common Equity	0.00	0.27	0.46
Other Financing Activities, net	2.89	1.87	1.60

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-66	-32	27	17	-5.39	-2.67	-24	15	-0.56	-9.07
Net Cash From Operating Activities	-5.92	-6.09	-4.32	-10	-8.24	0.98	-11	-4.83	-4.39	-7.82
Net Cash From Continuing Operating Activities	-5.92	-6.09	-4.32	-10	-8.24	0.98	-11	-4.83	-4.39	-7.82
Net Income / (Loss) Continuing Operations	-6.43	-4.81	-11	-11	-11	-5.28	-9.53	-9.38	-12	-11
Consolidated Net Income / (Loss)	-6.43	-4.81	-11	-11	-11	-5.28	-9.53	-9.38	-12	-11
Depreciation Expense	0.74	0.92	0.96	1.03	1.08	1.10	1.11	1.08	1.07	1.06
Amortization Expense	-0.95	-1.51	-1.73	-1.91	-1.48	-1.60	-1.98	-1.68	-1.39	-0.72
Non-Cash Adjustments To Reconcile Net Income	3.82	6.26	4.46	4.84	1.69	5.89	3.17	3.82	4.52	4.15
Changes in Operating Assets and Liabilities, net	-3.09	-6.95	2.86	-3.55	1.73	0.87	-3.34	1.33	2.97	-1.71
Net Cash From Investing Activities	-61	-27	30	27	2.81	-4.14	-14	19	3.61	-1.67
Net Cash From Continuing Investing Activities	-61	-27	30	27	2.81	-4.14	-14	19	3.61	-1.67
Purchase of Property, Plant & Equipment	-3.48	-2.19	-1.56	-0.51	-0.72	-0.92	-0.80	-0.29	-0.41	-0.15
Purchase of Investments	-82	-77	-58	-47	-81	-69	-48	-31	-39	-33
Sale and/or Maturity of Investments	25	53	89	74	84	66	34	51	43	31
Net Cash From Financing Activities	0.44	1.23	1.46	0.16	0.04	0.49	0.70	0.71	0.23	0.41
Net Cash From Continuing Financing Activities	0.44	1.23	1.46	0.16	0.04	0.49	0.70	0.71	0.23	0.41
Issuance of Common Equity	-	-	0.00	-	-	0.27	0.00	0.27	-	0.19
Other Financing Activities, net	0.44	1.23	1.46	0.16	0.04	0.22	0.70	0.45	0.23	0.22

This table presents MaxCyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	287	268	239
Total Current Assets	252	190	172
Cash & Equivalents	11	47	28
Short-Term Investments	216	122	127
Accounts Receivable	13	5.78	4.68
Inventories, net	8.58	12	8.91
Prepaid Expenses	3.26	3.90	3.61
Plant, Property, & Equipment, net	24	24	20
Total Noncurrent Assets	11	55	48
Long-Term Investments	0.00	43	36
Other Noncurrent Operating Assets	11	12	12
Total Liabilities & Shareholders' Equity	287	268	239
Total Liabilities	33	36	33
Total Current Liabilities	15	18	16
Accounts Payable	0.29	0.74	1.36
Accrued Expenses	8.27	11	8.30
Current Deferred Revenue	6.71	5.07	5.25
Other Current Liabilities	0.16	0.77	0.86
Total Noncurrent Liabilities	17	18	17
Other Noncurrent Operating Liabilities	17	18	17
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	254	232	206
Total Preferred & Common Equity	254	232	206
Preferred Stock	0.00	0.00	0.00
Total Common Equity	254	232	206
Common Stock	392	408	423
Retained Earnings	-138	-176	-217

This table presents MaxCyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	286	282	271	267	258	251	249
Total Current Assets	252	246	237	214	179	176	173
Cash & Equivalents	43	38	55	49	22	38	37
Short-Term Investments	190	187	162	141	135	120	117
Accounts Receivable	8.21	9.29	7.61	8.17	5.99	4.58	4.56
Inventories, net	7.91	10	11	13	12	11	10
Prepaid Expenses	3.28	2.23	1.88	3.40	3.21	2.58	4.12
Plant, Property, & Equipment, net	23	25	24	24	23	22	21
Total Noncurrent Assets	11	10	10	29	56	54	55
Long-Term Investments	-	-	-	18	45	42	43
Other Noncurrent Operating Assets	11	10	10	10	11	12	12
Total Liabilities & Shareholders' Equity	286	282	271	267	258	251	249
Total Liabilities	32	34	30	33	32	30	35
Total Current Liabilities	17	17	13	17	13	12	18
Accounts Payable	2.09	3.50	1.60	0.45	1.67	0.95	1.87
Accrued Expenses	8.23	6.91	6.41	9.92	6.50	7.08	8.20
Current Deferred Revenue	6.29	5.75	4.69	5.59	4.48	3.37	6.65
Other Current Liabilities	0.15	0.48	0.50	0.70	0.83	0.88	0.91
Total Noncurrent Liabilities	15	17	17	17	18	18	18
Other Noncurrent Operating Liabilities	15	17	17	17	18	18	18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	254	248	241	233	226	221	213
Total Preferred & Common Equity	254	248	241	233	226	221	213
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	254	248	241	233	226	221	213
Common Stock	387	397	400	404	412	416	420
Retained Earnings	-133	-149	-159	-171	-185	-195	-206

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	30.59%	-6.72%	-6.45%
EBITDA Growth	-62.34%	-86.07%	-3.53%
EBIT Growth	-50.43%	-76.53%	-6.00%
NOPAT Growth	-50.43%	-76.53%	-6.00%
Net Income Growth	-23.52%	-60.89%	-8.26%
EPS Growth	-9.52%	-60.87%	-5.41%
Operating Cash Flow Growth	-38.42%	-46.70%	-27.32%
Free Cash Flow Firm Growth	-120.44%	25.85%	-9.82%
Invested Capital Growth	239.07%	-21.36%	-23.65%
Revenue Q/Q Growth	5.41%	8.52%	-15.29%
EBITDA Q/Q Growth	-11.28%	-2.53%	-7.27%
EBIT Q/Q Growth	-7.02%	-2.86%	-10.36%
NOPAT Q/Q Growth	-7.02%	-2.86%	-10.36%
Net Income Q/Q Growth	0.27%	-1.25%	-14.88%
EPS Q/Q Growth	-4.55%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-53.08%	24.58%	-46.80%
Free Cash Flow Firm Q/Q Growth	0.00%	21.94%	-26.37%
Invested Capital Q/Q Growth	23.58%	-15.24%	-4.11%
Profitability Metrics	-	-	-
Gross Margin	88.48%	88.51%	81.62%
EBITDA Margin	-61.75%	-123.17%	-136.30%
Operating Margin	-61.82%	-116.98%	-132.54%
EBIT Margin	-61.82%	-116.98%	-132.54%
Profit (Net Income) Margin	-53.25%	-91.85%	-106.29%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	86.15%	78.52%	80.19%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-111.09%	-142.15%	-194.09%
ROIC Less NNEP Spread (ROIC-NNEP)	-109.26%	-140.27%	-191.49%
Return on Net Nonoperating Assets (RNNOA)	101.97%	126.55%	175.36%
Return on Equity (ROE)	-9.12%	-15.60%	-18.73%
Cash Return on Invested Capital (CROIC)	-219.99%	-118.24%	-167.27%
Operating Return on Assets (OROA)	-9.59%	-17.41%	-20.17%
Return on Assets (ROA)	-8.26%	-13.67%	-16.17%
Return on Common Equity (ROCE)	-9.12%	-15.60%	-18.73%
Return on Equity Simple (ROE_SIMPLE)	-9.28%	-16.33%	-19.91%
Net Operating Profit after Tax (NOPAT)	-19	-34	-36
NOPAT Margin	-43.27%	-81.89%	-92.78%
Net Nonoperating Expense Percent (NNEP)	-1.83%	-1.88%	-2.60%
Return On Investment Capital (ROIC_SIMPLE)	-	-14.56%	-17.38%
Cost of Revenue to Revenue	11.52%	11.49%	18.38%
SG&A Expenses to Revenue	58.36%	72.83%	76.87%
R&D to Revenue	44.09%	57.69%	57.54%
Operating Expenses to Revenue	150.30%	205.50%	214.16%
Earnings before Interest and Taxes (EBIT)	-27	-48	-51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-51	-53
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.19	2.10	2.13
Price to Tangible Book Value (P/TBV)	2.19	2.10	2.13
Price to Revenue (P/Rev)	12.59	11.79	11.36
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.39	13.16	15.55
Enterprise Value to Revenue (EV/Rev)	7.45	6.67	6.43
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.93	-0.90	-0.92
Leverage Ratio	1.10	1.14	1.16
Compound Leverage Factor	0.95	0.90	0.93
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	10.39	7.50	6.90
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	16.35	10.65	10.88
Quick Ratio	15.58	9.75	10.09
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-28	-31
Operating Cash Flow to CapEx	-80.01%	-587.54%	-1,672.32%
Free Cash Flow to Firm to Interest Expense	-298.64	0.00	0.00
Operating Cash Flow to Interest Expense	-116.40	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-261.89	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.16	0.15	0.15
Accounts Receivable Turnover	4.43	4.38	7.39
Inventory Turnover	0.74	0.46	0.67
Fixed Asset Turnover	2.82	1.75	1.79
Accounts Payable Turnover	4.83	9.16	6.76
Days Sales Outstanding (DSO)	82.32	83.39	49.42
Days Inventory Outstanding (DIO)	493.50	800.89	543.46
Days Payable Outstanding (DPO)	75.62	39.83	54.00
Cash Conversion Cycle (CCC)	500.20	844.44	538.88
Capital & Investment Metrics	-	-	-
Invested Capital	27	21	16
Invested Capital Turnover	2.57	1.74	2.09
Increase / (Decrease) in Invested Capital	19	-5.69	-4.95
Enterprise Value (EV)	330	276	249
Market Capitalization	557	487	439
Book Value per Share	$2.49	$2.24	$1.96
Tangible Book Value per Share	$2.49	$2.24	$1.96
Total Capital	254	232	206
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-227	-211	-190
Capital Expenditures (CapEx)	18	3.69	1.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.50	4.05	1.43
Debt-free Net Working Capital (DFNWC)	237	172	156
Net Working Capital (NWC)	237	172	156
Net Nonoperating Expense (NNE)	4.42	4.11	5.22
Net Nonoperating Obligations (NNO)	-227	-211	-190
Total Depreciation and Amortization (D&A)	0.03	-2.55	-1.45
Debt-free, Cash-free Net Working Capital to Revenue	21.46%	9.81%	3.69%
Debt-free Net Working Capital to Revenue	535.10%	417.41%	403.63%
Net Working Capital to Revenue	535.10%	417.41%	403.63%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.23)	($0.37)	($0.39)
Adjusted Weighted Average Basic Shares Outstanding	101.70M	103.27M	104.85M
Adjusted Diluted Earnings per Share	($0.23)	($0.37)	($0.39)
Adjusted Weighted Average Diluted Shares Outstanding	101.70M	103.27M	104.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	102.90M	104.13M	106.03M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-34	-36
Normalized NOPAT Margin	-43.27%	-81.89%	-92.78%
Pre Tax Income Margin	-53.25%	-91.85%	-106.29%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-215.44	0.00	0.00
NOPAT to Interest Expense	-150.81	0.00	0.00
EBIT Less CapEx to Interest Expense	-360.93	0.00	0.00
NOPAT Less CapEx to Interest Expense	-296.30	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.97%	22.37%	-25.99%	-5.88%	-24.79%	26.10%	32.25%	15.33%	2.00%	-44.51%
EBITDA Growth	-273.94%	-60.62%	-276.42%	-66.88%	-81.20%	-17.11%	5.73%	9.95%	-0.15%	-46.10%
EBIT Growth	-215.69%	-36.23%	-216.85%	-49.60%	-80.91%	-19.92%	6.85%	8.45%	-0.72%	-59.35%
NOPAT Growth	-215.69%	-36.23%	-216.85%	-49.60%	-80.91%	-19.92%	6.85%	8.45%	-0.72%	-59.35%
Net Income Growth	-140.03%	1.33%	-167.55%	-27.26%	-74.88%	-9.73%	12.46%	10.82%	-2.72%	-100.78%
EPS Growth	-100.00%	-25.00%	0.00%	-25.00%	-83.33%	0.00%	0.00%	10.00%	0.00%	0.00%
Operating Cash Flow Growth	-757.56%	-533.83%	-17.05%	-1,200.04%	-39.13%	116.12%	-144.31%	52.16%	46.70%	-897.25%
Free Cash Flow Firm Growth	-88.35%	0.00%	-11.38%	-9.78%	30.93%	100.08%	50.32%	72.73%	86.06%	-20,694.44%
Invested Capital Growth	161.88%	239.07%	68.00%	56.84%	14.67%	-21.36%	2.80%	-13.76%	-32.52%	-23.65%
Revenue Q/Q Growth	10.77%	16.73%	-30.97%	5.45%	-11.49%	95.71%	-27.59%	-8.05%	-21.72%	6.47%
EBITDA Q/Q Growth	5.30%	7.34%	-90.01%	-0.09%	-2.83%	40.11%	-46.24%	4.40%	-14.36%	12.63%
EBIT Q/Q Growth	11.75%	12.46%	-95.20%	0.80%	-6.72%	41.97%	-51.63%	2.50%	-17.42%	8.20%
NOPAT Q/Q Growth	11.75%	12.46%	-95.20%	0.80%	-6.72%	41.97%	-51.63%	2.50%	-17.42%	8.20%
Net Income Q/Q Growth	22.11%	25.24%	-126.25%	3.40%	-7.03%	53.09%	-80.51%	1.59%	-23.27%	8.31%
EPS Q/Q Growth	25.00%	16.67%	0.00%	0.00%	-10.00%	0.00%	0.00%	0.00%	-22.22%	0.00%
Operating Cash Flow Q/Q Growth	-744.57%	-2.79%	28.96%	-133.70%	18.48%	111.91%	-1,176.09%	54.24%	9.16%	-78.11%
Free Cash Flow Firm Q/Q Growth	-13.11%	-25.55%	20.85%	2.34%	28.84%	100.15%	-45,646.57%	46.40%	63.61%	-126.20%
Invested Capital Q/Q Growth	35.86%	23.58%	-13.00%	7.37%	-0.67%	-15.24%	13.72%	-9.93%	-22.27%	-4.11%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.14%	87.55%	88.34%	84.78%	90.09%	89.96%	87.63%	85.73%	76.38%	73.76%
EBITDA Margin	-74.43%	-59.08%	-162.62%	-154.35%	-179.32%	-54.87%	-115.91%	-120.52%	-176.07%	-144.49%
Operating Margin	-72.46%	-54.34%	-153.66%	-144.56%	-174.31%	-51.68%	-108.23%	-114.76%	-172.13%	-148.42%
EBIT Margin	-72.46%	-54.34%	-153.66%	-144.56%	-174.31%	-51.68%	-108.23%	-114.76%	-172.13%	-148.42%
Profit (Net Income) Margin	-60.45%	-38.72%	-126.89%	-116.24%	-140.57%	-33.69%	-83.99%	-89.89%	-141.56%	-121.92%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	83.42%	71.25%	82.58%	80.41%	80.64%	65.19%	77.60%	78.33%	82.24%	82.14%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-143.07%	-97.66%	-240.12%	-202.15%	-200.73%	-62.80%	-142.08%	-157.59%	-265.56%	-217.35%
ROIC Less NNEP Spread (ROIC-NNEP)	-142.65%	-97.62%	-239.42%	-201.55%	-200.06%	-62.98%	-141.64%	-157.11%	-264.71%	-216.57%
Return on Net Nonoperating Assets (RNNOA)	134.46%	91.11%	222.07%	185.08%	181.09%	56.82%	127.61%	141.37%	240.19%	198.33%
Return on Equity (ROE)	-8.61%	-6.55%	-18.05%	-17.07%	-19.64%	-5.99%	-14.47%	-16.22%	-25.37%	-19.02%
Cash Return on Invested Capital (CROIC)	0.00%	-219.99%	-188.56%	-184.19%	-155.79%	-118.24%	-144.00%	-125.12%	-118.12%	-167.27%
Operating Return on Assets (OROA)	-10.79%	-8.43%	-22.14%	-20.97%	-23.98%	-7.69%	-17.68%	-19.95%	-30.46%	-22.58%
Return on Assets (ROA)	-9.00%	-6.00%	-18.29%	-16.86%	-19.34%	-5.01%	-13.72%	-15.63%	-25.05%	-18.55%
Return on Common Equity (ROCE)	-8.61%	-6.55%	-18.05%	-17.07%	-19.64%	-5.99%	-14.47%	-16.22%	-25.37%	-19.02%
Return on Equity Simple (ROE_SIMPLE)	-9.29%	0.00%	-12.26%	-13.54%	-16.05%	0.00%	-16.15%	-16.01%	-16.75%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.40	-4.73	-9.22	-9.15	-9.77	-5.67	-8.59	-8.38	-9.84	-9.03
NOPAT Margin	-50.72%	-38.04%	-107.56%	-101.20%	-122.02%	-36.18%	-75.76%	-80.33%	-120.49%	-103.90%
Net Nonoperating Expense Percent (NNEP)	-0.42%	-0.03%	-0.70%	-0.60%	-0.67%	0.18%	-0.44%	-0.48%	-0.85%	-0.78%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-2.44%	-	-	-	-4.38%
Cost of Revenue to Revenue	12.86%	12.45%	11.66%	15.22%	9.91%	10.04%	12.37%	14.27%	23.62%	26.24%
SG&A Expenses to Revenue	60.55%	45.48%	87.44%	84.74%	85.21%	51.62%	62.63%	73.25%	94.87%	82.90%
R&D to Revenue	50.03%	46.10%	70.51%	62.63%	78.26%	37.29%	58.88%	53.88%	65.12%	53.08%
Operating Expenses to Revenue	159.60%	141.90%	242.00%	229.35%	264.41%	141.64%	195.86%	200.49%	248.52%	222.18%
Earnings before Interest and Taxes (EBIT)	-7.71	-6.75	-13	-13	-14	-8.10	-12	-12	-14	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.92	-7.34	-14	-14	-14	-8.60	-13	-13	-14	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.60	2.19	2.06	1.96	1.38	2.10	1.93	1.85	1.92	2.13
Price to Tangible Book Value (P/TBV)	2.60	2.19	2.06	1.96	1.38	2.10	1.93	1.85	1.92	2.13
Price to Revenue (P/Rev)	15.75	12.59	12.35	11.63	8.49	11.79	9.90	9.02	8.96	11.36
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.88	12.39	12.29	10.33	4.62	13.16	9.82	9.79	12.73	15.55
Enterprise Value to Revenue (EV/Rev)	10.20	7.45	6.90	6.31	3.00	6.67	5.31	4.62	4.65	6.43
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.94	-0.93	-0.93	-0.92	-0.91	-0.90	-0.90	-0.90	-0.91	-0.92
Leverage Ratio	1.09	1.10	1.12	1.13	1.13	1.14	1.14	1.13	1.15	1.16
Compound Leverage Factor	0.91	0.79	0.93	0.91	0.91	0.74	0.88	0.89	0.95	0.95
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	12.80	10.62	9.29	9.55	5.77	8.00	8.07	7.85	6.53	7.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	15.05	16.35	14.81	17.92	12.87	10.65	13.26	14.31	9.81	10.88
Quick Ratio	14.38	15.58	14.06	16.94	11.92	9.75	12.13	13.19	8.99	10.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-19	-24	-19	-18	-13	0.02	-9.24	-4.95	-1.80	-4.08
Operating Cash Flow to CapEx	-170.25%	-277.36%	-279.15%	-1,993.10%	-1,144.17%	107.21%	-1,313.93%	-1,644.22%	-1,081.53%	-5,320.41%
Free Cash Flow to Firm to Interest Expense	-161.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-51.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-81.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.16	0.14	0.15	0.14	0.15	0.16	0.17	0.18	0.15
Accounts Receivable Turnover	5.93	4.43	4.60	5.41	4.65	4.38	5.77	7.46	7.17	7.39
Inventory Turnover	0.79	0.74	0.60	0.56	0.46	0.46	0.46	0.47	0.56	0.67
Fixed Asset Turnover	2.82	2.82	2.16	1.81	1.63	1.75	1.85	1.97	2.04	1.79
Accounts Payable Turnover	3.40	4.83	1.28	2.61	3.72	9.16	1.99	4.11	5.53	6.76
Days Sales Outstanding (DSO)	61.57	82.32	79.28	67.47	78.55	83.39	63.31	48.95	50.93	49.42
Days Inventory Outstanding (DIO)	460.65	493.50	610.57	646.47	791.31	800.89	788.35	769.97	654.56	543.46
Days Payable Outstanding (DPO)	107.34	75.62	285.16	140.01	98.06	39.83	183.60	88.73	66.00	54.00
Cash Conversion Cycle (CCC)	414.89	500.20	404.70	573.93	771.80	844.44	668.05	730.20	639.50	538.88
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	22	27	23	25	25	21	24	21	17	16
Invested Capital Turnover	2.82	2.57	2.23	2.00	1.65	1.74	1.88	1.96	2.20	2.09
Increase / (Decrease) in Invested Capital	13	19	9.38	9.01	3.16	-5.69	0.65	-3.42	-8.03	-4.95
Enterprise Value (EV)	428	330	285	257	114	276	234	210	212	249
Market Capitalization	661	557	509	473	323	487	436	410	409	439
Book Value per Share	$2.50	$2.49	$2.41	$2.34	$2.25	$2.24	$2.17	$2.12	$2.03	$1.96
Tangible Book Value per Share	$2.50	$2.49	$2.41	$2.34	$2.25	$2.24	$2.17	$2.12	$2.03	$1.96
Total Capital	254	254	248	241	233	232	226	221	213	206
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-233	-227	-225	-216	-209	-211	-203	-200	-197	-190
Capital Expenditures (CapEx)	3.48	2.19	1.55	0.51	0.72	0.92	0.80	0.29	0.41	0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.63	9.50	5.15	7.31	7.45	4.05	7.68	6.04	1.46	1.43
Debt-free Net Working Capital (DFNWC)	236	237	230	223	198	172	165	163	155	156
Net Working Capital (NWC)	236	237	230	223	198	172	165	163	155	156
Net Nonoperating Expense (NNE)	1.04	0.08	1.66	1.36	1.48	-0.39	0.93	1.00	1.72	1.57
Net Nonoperating Obligations (NNO)	-233	-227	-225	-216	-209	-211	-203	-200	-197	-190
Total Depreciation and Amortization (D&A)	-0.21	-0.59	-0.77	-0.89	-0.40	-0.50	-0.87	-0.60	-0.32	0.34
Debt-free, Cash-free Net Working Capital to Revenue	6.27%	21.46%	12.48%	17.96%	19.58%	9.81%	17.44%	13.30%	3.19%	3.69%
Debt-free Net Working Capital to Revenue	560.89%	535.10%	557.10%	549.13%	519.61%	417.41%	374.99%	359.53%	340.54%	403.63%
Net Working Capital to Revenue	560.89%	535.10%	557.10%	549.13%	519.61%	417.41%	374.99%	359.53%	340.54%	403.63%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	($0.05)	($0.11)	($0.10)	($0.11)	($0.05)	($0.09)	($0.09)	($0.11)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	101.81M	101.70M	102.85M	103.06M	103.45M	103.27M	104.09M	104.64M	105.11M	104.85M
Adjusted Diluted Earnings per Share	($0.06)	($0.05)	($0.11)	($0.10)	($0.11)	$0.00	$0.00	($0.09)	($0.11)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	101.81M	101.70M	102.85M	103.06M	103.45M	103.27M	104.54M	104.64M	105.11M	104.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	102.05M	102.90M	103.05M	103.50M	103.58M	104.13M	104.54M	105.09M	105.48M	106.03M
Normalized Net Operating Profit after Tax (NOPAT)	-5.40	-4.73	-9.22	-9.15	-9.77	-5.67	-8.59	-8.38	-9.84	-9.03
Normalized NOPAT Margin	-50.72%	-38.04%	-107.56%	-101.20%	-122.02%	-36.18%	-75.76%	-80.33%	-120.49%	-103.90%
Pre Tax Income Margin	-60.45%	-38.72%	-126.89%	-116.24%	-140.57%	-33.69%	-83.99%	-89.89%	-141.56%	-121.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-66.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-46.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-96.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-76.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About MaxCyte's Financials

When does MaxCyte's financial year end?

According to the most recent income statement we have on file, MaxCyte's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has MaxCyte's net income changed over the last 2 years?

MaxCyte's net income appears to be on an upward trend, with a most recent value of -$41.06 million in 2024, rising from -$23.57 million in 2022. The previous period was -$37.92 million in 2023. See where experts think MaxCyte is headed by visiting MaxCyte's forecast page.

What is MaxCyte's operating income?

MaxCyte's total operating income in 2024 was -$51.20 million, based on the following breakdown:

Total Gross Profit: $31.53 million
Total Operating Expenses: $82.72 million

How has MaxCyte revenue changed over the last 2 years?

Over the last 2 years, MaxCyte's total revenue changed from $44.26 million in 2022 to $38.63 million in 2024, a change of -12.7%.

How much debt does MaxCyte have?

MaxCyte's total liabilities were at $33.22 million at the end of 2024, a 8.0% decrease from 2023, and a 1.6% increase since 2022.

How much cash does MaxCyte have?

In the past 2 years, MaxCyte's cash and equivalents has ranged from $11.07 million in 2022 to $46.51 million in 2023, and is currently $27.88 million as of their latest financial filing in 2024.

How has MaxCyte's book value per share changed over the last 2 years?

Over the last 2 years, MaxCyte's book value per share changed from 2.49 in 2022 to 1.96 in 2024, a change of -21.4%.

Related Companies

This page (NASDAQ:MXCT) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Financials

Frequently Asked Questions About MaxCyte's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Financials

Annual Income Statements for MaxCyte

Quarterly Income Statements for MaxCyte

Annual Cash Flow Statements for MaxCyte

Quarterly Cash Flow Statements for MaxCyte

Annual Balance Sheets for MaxCyte

Quarterly Balance Sheets for MaxCyte

Annual Metrics and Ratios for MaxCyte

Quarterly Metrics and Ratios for MaxCyte

Frequently Asked Questions About MaxCyte's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools